{"id":"azd5148","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AZD5148 works by blocking the action of adenosine at the A2A receptor, which is involved in the regulation of inflammation and immune responses. This blockade is thought to contribute to its therapeutic effects in various diseases.","oneSentence":"AZD5148 is a selective, potent and orally bioavailable adenosine A2A receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:30:25.393Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07285213","phase":"PHASE2","title":"Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-10","conditions":"Clostridioides Difficile Infection","enrollment":230},{"nctId":"NCT06639997","phase":"PHASE1","title":"Safety and Tolerability of AZD5148 in Japanese Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-10-31","conditions":"Clostridioides Difficile Infection","enrollment":16},{"nctId":"NCT06469151","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD5148 in Healthy Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-06-24","conditions":"Healthy Participants","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AZD5148","genericName":"AZD5148","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD5148 is a selective, potent and orally bioavailable adenosine A2A receptor antagonist. Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}